Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab Combinations vs Pembrolizumab in First-Line PD-L1 High NSCLC
NCT03515629Phase 3Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jul 2018
- Primary completion
- Jul 2021
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of cemiplimab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Progression-Free Survival up to 32 months. Started Jul 2018; status: terminated.
02
Drugs
cemiplimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03515629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03515629.